| scholarly article | Q13442814 |
| P50 | author | David E. Gerber | Q56107235 |
| Muhammad S Beg | Q92024135 | ||
| P2093 | author name string | David A Boothman | |
| Ralph J Deberardinis | |||
| Xian-Jin Xie | |||
| Matthew E Merritt | |||
| Daniel Laheru | |||
| Richard Leff | |||
| Xiumei Huang | |||
| Venetia Sarode | |||
| Molly A Silvers | |||
| Farjana Fattah | |||
| Joyce Bolluyt | |||
| P2860 | cites work | Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy | Q27346846 |
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis | Q28242612 | ||
| Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine | Q29616728 | ||
| Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy | Q33753357 | ||
| Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers. | Q33775762 | ||
| Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma | Q34642090 | ||
| An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone | Q35880201 | ||
| DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours | Q36431207 | ||
| Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC. | Q36471467 | ||
| New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors | Q36547381 | ||
| Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: combining drugs imposes different artificial checkpoints | Q36673922 | ||
| An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis | Q36695591 | ||
| Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. | Q36697159 | ||
| Dose escalation methods in phase I cancer clinical trials | Q37198192 | ||
| Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers | Q37254021 | ||
| Synergistic effect of ionizing radiation and beta-Lapachone against RKO human colon adenocarcinoma cells | Q37446989 | ||
| Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. | Q38726394 | ||
| Cancer Statistics, 2017. | Q39038674 | ||
| Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone | Q40105438 | ||
| NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity | Q40899393 | ||
| Prostate Cancer Radiosensitization through Poly(ADP-Ribose) Polymerase-1 Hyperactivation | Q42409402 | ||
| Paclitaxel and beta-lapachone synergistically induce apoptosis in human retinoblastoma Y79 cells by downregulating the levels of phospho-Akt. | Q43240729 | ||
| Calcium is a key signaling molecule in beta-lapachone-mediated cell death | Q43560312 | ||
| μ-Calpain Activation in β-Lapachone-Mediated Apoptosis | Q44443361 | ||
| Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1. | Q45232206 | ||
| NQO1 expression in pancreatic cancer and its potential use as a biomarker | Q46842656 | ||
| Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas | Q46987425 | ||
| Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer | Q57272650 | ||
| Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis | Q57461599 | ||
| Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and Survival | Q77376768 | ||
| BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer | Q77635783 | ||
| Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair | Q80141901 | ||
| P433 | issue | 1 | |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 83-88 | |
| P577 | publication date | 2017-03-27 | |
| P1433 | published in | Journal of Surgical Oncology | Q1919535 |
| P1476 | title | Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer | |
| P478 | volume | 116 |
| Q54989340 | A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology |
| Q47574066 | Accelerating progress in the fight against pancreatic cancer Proceedings of the 2017 Leo and Anne Albert Symposium for Pancreatic Cancer Research. |
| Q90494760 | Alteration of Cellular Reduction Potential Will Change 64Cu-ATSM Signal With or Without Hypoxia |
| Q89484746 | Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone |
| Q94561568 | Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer |
| Q88646457 | Pancreatic Cancer Metabolism: Molecular Mechanisms and Clinical Applications |
| Q89340953 | Treating pancreatic cancer: more antioxidants more problems? |
| Q50200648 | Trypanosoma cruzi: death phenotypes induced by ortho-naphthoquinone substrates of the aldo-keto reductase (TcAKR). Role of this enzyme in the mechanism of action of β-lapachone |
Search more.